Evidence map›Paper›PMID 27682269›Full record

ArticleScientific reports2016

The Golgi associated ERI3 is a Flavivirus host factor.

Alex Michael Ward, Meredith E K Calvert, Leah R Read, Seokyoung Kang, Brandt E Levitt, George Dimopoulos, Shelton S Bradrick, Jayantha Gunaratne, Mariano A Garcia-Blanco

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Universal RNAFrontiers in microbiology · 2020
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Cellular Targets for the Treatment of Flavivirus Infections.Frontiers in cellular and infection microbiology · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Alex Michael WardProgram in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.
Meredith E K CalvertBioimaging &Biocomputing Facility, Temasek Lifesciences Laboratory, Singapore.
Leah R ReadProgram in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.
Seokyoung KangW. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Brandt E LevittCenter for RNA Biology and Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
George DimopoulosW. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Shelton S BradrickCenter for RNA Biology and Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Jayantha GunaratneTranslational Biomedical Proteomics Laboratory, Institute of Molecular and Cell Biology, Singapore.
Mariano A Garcia-BlancoProgram in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.
Duke-NUS Medical School · SGJohns Hopkins University · USDuke Medical Center · USNational University of Singapore · SGTemasek Life Sciences Laboratory · SGThe University of Texas Medical Branch at Galveston · US

Funding

Targeting dengue in the mosquito with small moleculesR01AI101431 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DIMOPOULOS, GEORGE, ENGEL, DANIEL A · 2012 to 2016
$4.3M
NIAID NIH HHS R01 AI101431
6 · The paper itself

Abstract

Dengue virus (DENV) is a mosquito-borne Flavivirus classified into four serotypes (DENV-1-4) that causes Dengue fever (DF), Dengue hemorrhagic Fever (DHF) or Dengue shock syndrome (DSS). An estimated 390 million people are at risk for infection with DENV and there are no effective vaccines or therapeutics. We utilized RNA chromatography coupled with quantitative mass spectrometry (qMS) to identify host RNA binding proteins (RBPs) that interact with DENV-2 RNA. We identified ERI3 (also PRNPIP and PINT1), a putative 3'-5' RNA exonuclease, which preferentially associates with DENV-2 genomic RNA via interactions with dumbbell structures in the 3' UTR. ERI3 is required for accumulation of DENV-2 genomic RNA and production of infectious particles. Furthermore, the mosquito homologue of ERI3 is required for DENV-2 replication in adult Aedes aegypti mosquitos implying that the requirement for ERI3 is conserved in both DENV hosts. In human cells ERI3 localizes to the Golgi in uninfected cells, but relocalizes near sites of DENV-2 replication in infected cells. ERI3 is not required for maintaining DENV-2 RNA stability or translation of the viral polyprotein, but is required for viral RNA synthesis. Our results define a specific role for ERI3 and highlight the importance of Golgi proteins in DENV-2 replication.

Identifiers

PMID27682269
PMCPMC5041148
OpenAlexW2527370163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.